New approach in the therapy of chronic rejection? ACE- and AT1-blocker reduce the development of chronic rejection after cardiac transplantation in a rat model.
BACKGROUND
Angiotensin II is one of the most potent mitogens of smooth muscle cell proliferation and plays a central role in the development of accelerated coronary artery disease (ACAD), which remains a serious consequence after heart transplantation and limits long-term survival. We investigated the effect of an angiotensin-II blocker, Losartan (angiotensin II Type 1 [AT(1)]-blocker), and an angiotensin-converting enzyme (ACE) inhibitor, Enalapril, on experimental ACAD in a rat cardiac transplant model (Fisher to Lewis).


METHODS
After grafting, recipients were treated with 10 mg/kg/day per os Losartan or 40 mg/kg/day per os Enalapril. Two groups of animals received additional pre-treatment with Losartan or Enalapril 7 days before transplantation. All study groups, including the control group, received immunosuppression with cyclosporine (3 mg/kg/day sub-cutaneously). We assessed the extent of ACAD of large and small arteries 80 days after grafting using digitizing morphometry.


RESULTS
We observed significant reduction of neointimal proliferation in small arteries in Losartan pre- and post-treated and in Enalapril pre-treated recipients compared with the cyclosporine-treated group (p < 0.05). In epicardial arteries, Enalapril pre- and post-treatment as well as Losartan post-treatment significantly reduced neointimal formation compared with the control group. Reduction of neointima by Enalapril post-treatment in small arteries and Losartan pre-treatment in large arteries trended toward but failed statistical significance.


CONCLUSIONS
Our results suggest the important role of the renin-angiotensin system in neointimal proliferation, which can be reduced equally with ACE inhibitors or the angiotensin-II blocker. Therefore AT(1) blockade with Losartan is a useful therapeutic strategy for inhibition of ACAD after cardiac transplantation.
Richter
M
M
Department of Cardiac Surgery, Heart Center, University of Leipzig, Leipzig, Germany. richtm@server3.medizin.uni-leipzig.de
Skupin
M
M
Grabs
R
R
Schramm
D
D
Richter
H
H
Olbrich
H G
HG
D000804:Angiotensin II / Q000037:antagonists & inhibitors*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D003327:Coronary Disease / Q000276:immunology / Q000473:pathology; D003331:Coronary Vessels / Q000473:pathology; D016572:Cyclosporine / Q000494:pharmacology; D004656:Enalapril / Q000494:pharmacology*; D006084:Graft Rejection / Q000276:immunology* / Q000473:pathology; D006085:Graft Survival / Q000187:drug effects; D016027:Heart Transplantation / Q000276:immunology* / Q000473:pathology; D007166:Immunosuppressive Agents / Q000494:pharmacology; D019808:Losartan / Q000494:pharmacology*; D008297:Male; D011292:Premedication; D051381:Rats; D011916:Rats, Inbred F344; D011917:Rats, Inbred Lew; D016042:Transplantation, Heterotopic
D000806:Angiotensin-Converting Enzyme Inhibitors; D007166:Immunosuppressive Agents; D000804:Angiotensin II; D004656:Enalapril; D016572:Cyclosporine; D019808:Losartan